Pre-Approval Information Exchange Act of 2022

Summary

Pre-Approval Information Exchange Act of 2022 This bill specifies that product information that is exchanged between drug manufacturers and certain health care entities (e.g., formulary committees) about drug products before regulatory approval is not considered to be misbranding if it relates to the product's investigational use and meets other specified criteria. The Government Accountability Office must study the use and effects of such information.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 15 November 2022

   Introduced

   Referred to the House Committee on Energy and Commerce.

   Source: IntroReferral

2. 15 November 2022

   Introduced

   Introduced in House

   Source: IntroReferral

3. 15 November 2022

   Introduced

   Introduced in House

   Source: IntroReferral

4. 16 November 2022

   Referred

   Referred to the Subcommittee on Health.

   Source: Committee

Votes

No vote records are attached yet.

Versions

• Introduced in House · 15 November 2022 · Download file

Documents

3 official files

• Introduced in House (text)

  Introduced in House · EN · 15 November 2022

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 15 November 2022

  ViewDownloadOpen at official source

  Leesvertaling

  Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

  Vertaal naarNL · DutchDE · GermanFR · FrenchES · SpanishIT · ItalianPL · PolishPT · PortugueseSV · SwedishDA · DanishFI · FinnishEL · GreekCS · CzechHU · HungarianRO · RomanianBG · BulgarianHR · CroatianSK · SlovakSL · SlovenianLT · LithuanianLV · LatvianET · EstonianGA · IrishMT · Maltese

  Vertaal document

  Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

• Introduced in House

  summary · EN · 15 November 2022

  Open at official source

  Leesvertaling

  Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

  Vertaal naarNL · DutchDE · GermanFR · FrenchES · SpanishIT · ItalianPL · PolishPT · PortugueseSV · SwedishDA · DanishFI · FinnishEL · GreekCS · CzechHU · HungarianRO · RomanianBG · BulgarianHR · CroatianSK · SlovakSL · SlovenianLT · LithuanianLV · LatvianET · EstonianGA · IrishMT · Maltese

  Vertaal document

  Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

• Rep. Guthrie, Brett [R-KY-2] · R · Sponsor
• Rep. Eshoo, Anna G. [D-CA-18] · D · Sponsor
• Rep. Griffith, H. Morgan [R-VA-9] · R · Sponsor
• Rep. Peters, Scott H. [D-CA-50] · D · Sponsor
• Rep. Burgess, Michael C. [R-TX-26] · R · Sponsor
• Rep. Matsui, Doris O. [D-CA-7] · D · Sponsor
• · hsif00 · Standing

Related records

• related to → Food and Drug Amendments of 2022